Clinical cross-reactivity between danaparoid and heparin antibodies successfully managed with bivalirudin

Isr Med Assoc J. 2009 Mar;11(3):188-90.

Authors

Maurice Shapiro¹, Johnathan Cohen, Aida Inbal, Pierre Singer

Affiliation

¹ Department of General Intensive Care, Rabin Medical Center, Beilinson Campus, Petah Tikvah and Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Israel. moriss@clalit.org.il

PMID: 19544713

No abstract available

Publication types

Case Reports

MeSH terms

Anticoagulants / immunology*
Anticoagulants / pharmacology
Antithrombins / therapeutic use*
Chondroitin Sulfates / immunology*
Chondroitin Sulfates / pharmacology
Cross Reactions / drug effects
Cross Reactions / immunology
Dermatan Sulfate / immunology*
Dermatan Sulfate / pharmacology
Heparinoids / adverse effects
Heparinoids / immunology
Heparitin Sulfate / immunology*
Heparitin Sulfate / pharmacology
Hirudins
Humans
Male
Middle Aged
Peptide Fragments / therapeutic use*
Platelet Aggregation / drug effects
Recombinant Proteins / therapeutic use
Thrombocytopenia / chemically induced

Substances

Anticoagulants
Antithrombins
Heparinoids
Hirudins
Peptide Fragments
Recombinant Proteins
Dermatan Sulfate
Chondroitin Sulfates
Heparitin Sulfate
danaparoid
bivalirudin